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Abstract 
Background: Biphasic mesothelioma (BPM) accounts for approximately 10% of all 
pleural mesothelioma. Our aim was to assess the clinical, radiological and 
pathological factors impacting survival in BPM and to better identify patients most 
likely to benefit from active treatment.  
Methods: Ten-year retrospective review of 214 biopsy-proven BPM cases with 
minimum 2-year follow-up. Patients with insufficient tissue for analysis were 
excluded (n=96). Clinical and pathological factors were evaluated along with 
radiological assessment of pleural thickness. Survival was measured from time of 
diagnosis. Uni- and multi-variable predictors of survival were evaluated. 
Results: 118 patients were included. 28 underwent pleurectomy/decortication (P/D), 
with 27 receiving additional modalities. 90 underwent chemotherapy (n=18) or 
radiotherapy alone (n=9), 63 received combination therapy, and 27 received best 
supportive care (BSC). Median overall survival was 11.2 months (0.3–36.2). At 
univariable analysis, P/D (p=0.0061), radiotherapy (RT; p<0.0001) and chemotherapy 
(p<0.0001) were associated with superior survival when compared to BSC alone. 
Pleurectomy-Decortication demonstrated 40% survival improvement compared with 
no surgery (p=0.122). In a multivariable model, the presence of necrosis was 
negatively prognostic (HR 2.1, SE 0.76). Furthermore, increased sarcomatoid 
component was associated with worse survival without radiotherapy. 
Conclusions: BPM prognosis remains poor despite multimodality treatment. Anti-
cancer treatment is associated with superior outcome in this non-randomised 
retrospective series. Our findings suggest superior survival for those with a lower 
proportion of sarcomatoid disease, with selective benefit of RT in higher proportions 
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of sarcomatoid disease. When planning active treatment, the potential survival 
benefits require balancing against associated morbidity and recovery period. 
 
Keywords: Biphasic Mesothelioma; Histopathology; Survival; 
Pleurectomy/decortication; radiotherapy 
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Malignant pleural mesothelioma (MPM) is a relatively rare but aggressive tumour arising 
from pleural mesothelial cells(1). Although its global incidence is unknown, records from the 
World Health Organisation report 92,253 MPM deaths in the period from 1994-2008, with 
the highest prevalence in the United States and the United Kingdom (18.5% and 14.6% of all 
recorded deaths respectively)(2). Its median overall survival from time of diagnosis is poor, 
ranging from 6 to 8 months without treatment(3). Chemotherapy, radiotherapy or 
multimodality therapy may improve survival, in some cases extending median survival to 
between 12 and 30 months(3-5).  
 
A number of clinical and pathological prognostic factors have been utilised to evaluate 
patients who may benefit from a multimodality approach to the treatment of MPM(6). These 
include patient-specific factors such as gender, age and performance status, as well as tumour 
factors including histological subtype (epithelioid vs. non epithelioid subtype), pleural 
thickening and clinical stage at presentation(7). For surgical patients, complete resection at 
the time of surgery, and pathological stage, are also associated with improved survival.(8) 
 
Owing to the small numbers of these patients seen by individual institutions, the majority of 
studies have grouped all subtypes of mesothelioma into single survival analyses. However, 
the importance of histologic subtype in determining both treatment and prognosis cannot be 
overlooked. Epithelioid MPM accounts for approximately 70% of all cases and is associated 
with the most favourable prognosis (median survival 14 months)(9). Conversely, sarcomatoid 
histology confers the worst overall survival characteristics and accounts for approximately 
20% of cases(9). Biphasic mesothelioma is characterized by the presence of both epithelioid 
and sarcomatoid components in variable proportions with at least 10% of either subtype(10). 
The prognosis of biphasic mesothelioma lies somewhere between that of epithelioid and 
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sarcomatoid disease; however, application of a similar multimodality approach to that 
successful in the treatment of isolated epitheloid MPM has yielded disappointing 
outcomes.(11)   
 
Despite the heterogeneous nature of biphasic MPM, it is yet to be further sub-classified 
according to its pathological and radiological features. The aim of this study was therefore to 
analyse the impact of radiological and pathological features on survival, and to determine 
which subgroup of patients with biphasic MPM may benefit from multimodality treatment.  
 
Material and Methods  
Between January 2005 and December 2015, a total of 489 patients presented to our institution 
with malignant pleural mesothelioma. 172 were diagnosed with epithelioid MPM, 66 with 
sarcomatoid, 12 with desmoplastic and 25 with unspecified malignant pleural mesothelioma 
and were excluded from the analysis. 
 
The remaining 214 patients with biopsy-proven biphasic mesothelioma were included in our 
analysis. Inclusion criteria were (1) biopsy-proven biphasic mesothelioma (defined as the 
simultaneous presence of both epithelioid and sarcomatoid components in any proportion 
between 1% and 99%(12)); (2) clinical data and slides available for analysis. Patients with no 
pathological slides available for review were excluded (n=96). The eligible 118 eligible 
patients were followed up until May 2016 (Figure 1). 
 
Demographics 
All clinical and pathological features were recorded and checked by two independent 
researchers.  Clinical factors included: age, gender, site of disease, clinical stage and 
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treatment modality (radiotherapy, chemotherapy, surgery). Disease features included: pleural 
thickness on computed tomography (CT), percentage of sarcomatoid component on 
histology, presence of necrosis, and pathological stage in patients who underwent surgery. 
 
Laboratory methods 
Two slides were reviewed for each patient by a specialist thoracic pathologist. Slides were 
stained with hematoxylin and eosin (H+E), digitally scanned and analysed using a 
Hamamatsu Nanozoomer scanner (Hamamatsu ‘NDP.View2’). Biphasic histology was 
defined as any MPM with between 1% and 99% of epithelioid differentiation. The proportion 
of epithelioid and sarcomatoid components on each slide was mapped and its area in mm2
  
recorded as a percentage of the total tumour area studied.  
 
Measurement of pleural thickness 
Pleural thickness was quantified based on computerised-tomography (CT) images obtained 
pre-operatively. A total of six measurements per scan were taken at two foci in accordance 
with the following criteria(13): (1) within 1cm of the aortic arch or lung apex, whichever was 
thicker; (2) within 1cm of the carina; (3) at the diaphragmatic base.  
 
Pleural thickness was obtained in 89 of the 100 patients with available imaging. Patients with 
exclusively pleural effusion without measurable pleural thickening were excluded (n=11).  
 
Statistical analysis 
Survival was measured from the date of diagnosis. All of the patients were followed up until 
death or for a minimum period of 2 years. All potential prognostic indices were measured at 
the time of diagnosis and evaluated as continuous or categorical variables. Continuous 
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variables were presented as median and range, and categorical variables as counts and 
percentage. Survival functions were computed using Kaplan-Meier estimators. Survival 
comparison between groups of patients was performed by means of the log-rank test. Factors 
that significantly affected survival in univariable analysis (defined as p<0.10) were selected 
alongside clinically relevant variables, as derived from the current literature, and incorporated 
into a multivariate analysis using a Cox proportional hazards model. The interactions of 
predictors selected for inclusion in the multivariable model were examined in a step-wise 
fashion. Interaction terms were included in the model where p<0.05. The final model was 
then checked to ensure no violation of the proportionality assumption. Results were reported 
as hazard ratios and 95% confidence intervals. A p value of <0.05 was considered statistically 
significant. All analyses were conducted using STATA version 12.0 (StataCorp, TX, USA)  
 
Results 
 One hundred and eighteen patients were included in the analysis. 106 (89.9%) were male and 
12 female. The median age was 73 years (range 53-91 years); 68% of the patients were older 
than 70 years. The site of the disease was the left pleura in 42 patients (36%) and the right 
pleura in 76 patients (64%). A full summary of patient characteristics is given in Table 1.  
 
The diagnosis of biphasic MPM was obtained by medical thoracoscopy in 7 patients (6%), 
cytology in 4, needle biopsy in 3, open pleural biopsy in 19 patients (16%), by video-assisted 
thoracoscopic surgery (VATS) pleural biopsy in 83 patients (70%), and by resection of 
pleural tumour in 2 patients.  
 
Following the initial procedure to establish the diagnosis, twenty-eight patients (23.7%) 
underwent pleurectomy/decortication (P/D). Ninety patients received medical treatment 
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alone, either with chemoradiation (n=35), chemotherapy only (n=18), radiotherapy only 
(n=9) or best supportive care (n=28) (Table 1).  
 
In the 28 patients who underwent P/D, the TNM pathological staging included stage IB in 2 
patients (7%), stage II in 2 patients (7%), and stage III in 24 patients (28%). A complete 
macroscopic resection was achieved in 6 patients (21%), an R1 status in 2 patients (7%) and 
R2 in 20 patients (72%). There was no postoperative mortality. Median length of hospital 
stay was 8 days (range 5-30 days). Twelve (42.9%) patients experienced postoperative 
complications, no patients required reoperation. Adjuvant therapy was offered to all patients 
undergoing surgery. Nineteen received chemo-radiotherapy (67%), 7 chemotherapy only 
(25%), and one patient refused adjuvant treatment.  
 
Survival Outcomes 
At the end of follow-up, 105 (89%) patients had died. Of the surviving patients, 6 had 
undergone prior P/D and 7 received medical treatment alone. Overall survival for the study 
population was 49.1% and 6.4 % at 1 and 2 years respectively. The median overall survival 
(OS) was 11.2 months (range 0.3-36.2) (Figure 2a).  
 
A summary of univariable results is shown in Table 2. Increasing age at diagnosis correlated 
with inferior overall survival (p=0.005, HR=1.03, SE 0.01; 95% CI 1.01-1.05). Conversely, 
surgery (pleurectomy/decortication; p=0.006), radiotherapy (p<0.0001) and chemotherapy 
(p=0.0001) were all independent predictors of improved overall survival. Notably, patients 
treated with P/D had an overall survival of 12.8 months (range 5.6-36.0), compared to 9.2 
months (range 0.3–31.8) in patients receiving medical treatment alone (Figure 2b). Overall 
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survival in patients undergoing pleurectomy-decortication was 82% at 1 year and 12% at 2 
years, compared with 40% at 1 year and 4% at 2 years in patients not receiving surgery.  
 
Neither gender, site of disease, the presence of necrosis, nor the extent of pleural thickening 
were significant predictors of overall survival. Notably, the overall survival at 1 and 2 years 
for patients with necrosis was 38% and 12%, respectively, compared to 52% and 5% in 
patients with no necrosis. However, this did not reach statistical significance (p=0.800). 
Similarly, the percentage sarcomatoid component did not significantly predict survival, either 
as a continuous (p=0.72) or dichotomized (<50% vs. ≥50%) variable (p=0.67) (Figure 3). 
Overall survival at 1 and 2 years for patients with <50% sarcomatoid component was 47% 
and 12%, compared with 52% and 4% in patients with ≥50% sarcomatoid component.  
 
The WHO classification of biphasic mesothelioma includes all patients with >10% or <90% 
of either histological component.(10) Consequently, a subgroup analysis was performed with 
revised inclusion criteria such that all patients with ≤10% (n=4) and >90% (n=21) 
sarcomatoid component were excluded. No significant difference was observed in any 
survival outcome when this subgroup was compared to the study population as a whole.  
 
The results of our multivariable model are shown in Table 3. In this model, when all other 
factors are held constant, the presence of tumour necrosis is associated with 2.1 times greater 
risk of death (HR 2.1). Pleurectomy/decortication was associated with improved survival (HR 
0.60), but this did not reach statistical significance (p=0.122). The presence of ≥50% 
sarcomatoid component was associated with 4.4 times greater risk of death when compared 
to <50% sarcomatoid component; however this has to be considered in the context of the 
statistically significant interaction of percentage sarcomatoid component and radiotherapy 
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within this model (p=0.001). This indicates that when comparing subjects who did not 
receive radiotherapy (RT=0), the presence of ≥50% sarcomatoid component yields a hazard 
ratio of 1.42 (exp[0.25]). Thus, the rate of death is 1.42 times higher when patients have 
≥50% sarcomatoid component. Comparing subjects who received radiotherapy (RT=1), the 
presence of ≥50% sarcomatoid component, yields a hazard ratio of 0.19 (exp[0.349 + -2.03]). 
Thus, in patients receiving radiotherapy the presence of ≥ 50% sarcomatoid component was 
associated with an 81.4% improvement in survival.  
 
Comment 
Malignant pleural mesothelioma (MPM) is notorious for poor clinical outcomes irrespective 
of stage and treatment modality. Median overall survival is only 9 months.  Chemotherapy 
may improve overall survival to around 12 months(14), with some further survival benefit 
seen in patients undergoing trimodality therapy, which includes macroscopic complete 
surgical resection of the tumour20. However, although survival of up to 30 months may be 
attained with a trimodality approach, these figures are predominantly confined to the 
epithelioid subtype of MPM, and patient selection remains paramount in achieving the best 
survival outcomes whilst minimising associated morbidity.(15, 16)  
It is well recognised that the strongest predictor for long-term survival in this disease is 
histological subtype, with pure epithelioid histology conferring the best prognosis(17, 18). In 
addition to performance status and clinical stage, histology plays a key role in determining 
the therapeutic strategy, with surgery usually reserved for purely epithelioid MPM. An 
aggressive approach to non-epithelioid MPM remains controversial, with surgery rarely 
offered in cases of sarcomatoid histology.  For cases of biphasic mesothelioma the role of 
surgical intervention remains unclear. Median survival for biphasic mesothelioma is reported 
as intermediate between the median survival for pure epithelioid or sarcomatoid histology           
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(approximately 8.4-13 months)(7, 16, 19-22), comparable to our results demonstrating a 
median overall survival of 11.2 months. 
 
The aim of this study was to determine significant prognostic factors in a specific cohort of 
patients with biphasic mesothelioma (BPM), in particular whether the proportion of 
sarcomatoid to epitheioid histology significantly affects survival outcomes. Furthermore, we 
aimed to determine whether there was any patient subgroup in which significant survival 
benefit may be gained from an aggressive multimodality approach. Some data addressing this 
question has previously been reported in previous studies. For patients undergoing surgery, 
superior survival has been reported for those with increased epithelioid component(12). 
Similarly, Alchami et al. showed a better overall survival in patients with epithelioid 
dominance, although this finding was not statistically significant(19). Our results demonstrate 
that chemotherapy, radiotherapy and pleurectomy/decortication are all associated with longer 
survival in biphasic mesothelioma, which may argue for using more aggressive trimodality 
therapy even in these patients. We also explored whether the extent of sarcomatoid 
component might be important. Although we demonstrate inferior survival in patients with 
≥50% compared to <50% sarcomatoid component (4% vs. 12% at 2 years) this did not reach 
statistical significance. However, at a multivariable level ≥50% sarcomatoid component was 
associated with a 1.42 times greater death rate in patients not receiving radiotherapy. 
Furthermore, those patients with ≥50% sarcomatoid component who did receive radiotherapy 
had an 81% improved survival when compared to those with <50%. As such, these results 
suggest that patients with higher proportions of sarcomatoid disease have worse survival 
outcomes without radiotherapy, but radiotherapy may be less effective at prolonging survival 
in epithelioid predominance. 
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The results of our series also demonstrate that extended pleurectomy-decortication did not 
significantly improve survival both at 1- (82% vs. 40%) and 2- (12.3% vs. 4.4%) years when 
compared to no surgical intervention at multivariable analysis. There are a number of reasons 
why this may be the case, firstly this is a non-randomised comparison and as such surgery is 
likely to also be associated with other factors such as performance status that have a more 
powerful effect on overall survival outcomes. Second, the relatively small number of patients 
undergoing P/D in this patient series (23.7%; 28/118) may also leave the study underpowered 
to detect significance at a multivariable level. Further research is therefore required to 
explore those patients with biphasic mesothelioma at greatest benefit from surgery as part of 
trimodality treatment.  
 
Another key element in determining the prognosis of BPM is the tumour volume (T value, 
TNM 7th edition) or pleural thickness. In their 2010 article, Liu et al(23) previously reported 
baseline tumour volume to be a significant predictor of survival (p=0.07), although the 
subtypes of MPM were not specified and this was not specific to BPM.  In their proposal 
regarding the T component of MPM for the forthcoming 8th TNM edition, Nowak et al(24) 
found that a minimal pattern of pleural thickening correlated with the best prognosis (median 
survival 23.4 months), compared with 18.2 months and 14.5 months with nodular and rind-
like patterns of pleural thickening respectively (nodular vs. minimal p=0.004; rindlike vs. 
minimal p=0.001). In our series, the radiological evaluation of pleural thickness was not a 
significant prognostic factor for survival (p=0.103; HR 1.008). We hypothesise that this 
finding may reflect the exclusive inclusion of BPM in this patient cohort. It is possible that 
the influence of the more aggressive and infiltrative sarcomatoid component outweighs the 
effect of pleural thickening in these patients and hence reduces its impact on overall survival.  
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This study is one of largest series of patients with exclusive biphasic mesothelioma (BPM) 
and includes patients at all stages undergoing surgical and non-surgical treatment. However, 
our results should be considered in the context of a number of limitations. Firstly, this is a 
retrospective single centre study performed over a 10-year period during which treatment 
approaches have been modified in accordance with clinical and technological developments. 
Second, in the majority of patients, diagnosis was made by pleural biopsy only, and as such 
the assessment of percentage sarcomatoid/epithelioid components is subject to the pleural 
sampling performed. Third, although 118 patients were included in this study, the number of 
surgical and non-surgical treatment modalities utilised results in a relatively small number of 
patients included in individual subgroups analysed. As such, the study may be underpowered 
to detect significant predictors of survival, particularly at the multivariable level given the 
interaction between multi-modal treatments and also the impact of extended surgery. Finally, 
it is important to note that treatment allocation in this retrospective series was not 
randomised, so interpretation of the efficacy of these therapies cannot be made with any 
certainty given the likelihood of selection bias.  
 
Conclusion 
The aggressive nature of biphasic malignant pleural mesothelioma (BPM) continues to 
represent a challenge to thoracic surgeons and oncologists. Our findings suggest that anti-
cancer treatment is associated with superior outcome in this non-randomised series, but 
selection bias must be considered in this context. We also show that patients with a higher 
percentage of sarcomatoid component may selectively benefit from radiotherapy as part of a 
multimodality approach. A larger prospective study is required to develop prognostic or 
predictive factors based on both tumour and patient characteristics and do determine the 
effect of multimodality approach in this specific group of patients.  
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Table 1. Patient characteristics (n=118) 
 
Variable Number % 
Age (yrs) 73 (53-91) 
< 70 36 30.5 
≥ 70 82 69.5 
Sex   
Male 106 89.9 
Female 12 10.1 
Comorbidities   
No  52 44.1 
Yes 66 55.9 
Type of comorbidity#   
COPD 4 3.4 
Coronary artery disease 11 9.3 
Atrial Fibrillation 1 0.85 
Hypertension 26 22.0 
Diabetes 17 8.5 
Previous cancer 6 4.1 
Smoking   
Yes 28 23.7 
No 2 1.4 
Unknown 89 75.4 
Asbesos exposure   
Yes 32 27.1 
No -  
Unknown 86 72.9 
Side   
Right 76 64.4 
Left 42 35.6 
Pleural thickness (mm) 38.8 (0-122) 
Necrosis   
Yes 18 15.3 
No 100 84.7 
Sarcomatoid component   
< 50% 39 33.1 
≥ 50% 79 66.9 
Treatment*   
Chemotherapy 81 68.6 
Radiotherapy 67 56.8 
Surgery (P/D) 28 23.7 
Best Supportive care 28 23.7 
 
*Some patients received a combination of treatment 
# Some patients had more than one comorbidities 
 
Continuous variables expressed as median (range) 
Categorical variables as count (%) 
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Table 2. Univariable analysis 
 
Continuous Variables Hazard ratio Standard Error 95% CI p 
Age 1.032 0.0115 1.010, 1.055 0.005** 
Pleural thickness 1.008 0.0048 0.998, 1.017 0.103 
Sarcomatoid component 
(continuous variable) 
1.001 0.0039 0.994, 1.006 0.723 
   
Categorical Variables Chi2 p 
Sex 0.02 0.8783 
Side of disease 0.10 0.7503 
Necrosis 0.06 0.8008 
Chemotherapy 50.12 <0.0001*** 
Radiotherapy 24.69 <0.0001*** 
Surgery 7.52 0.0061** 
Sarcomatoid component 
(dichotomous variable) 
0.19 0.6632 
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Table 3. Multivariable analysis: Overall model (with Hazard Ratios)– Likelihood ratio Chi2 = 61.98; 
Probability > Chi2  = <0.00001 
 
Variable HR SE of HR 95% CI  p 
Age 0.968 0.344 0.903, 1.038 0.364 
     
Treatment     
Chemotherapy 0.583 0.450 0.129, 2.647 0.485 
Radiotherapy 1.418 0.770 0.489, 4.109 0.520 
Surgery 0.601 0.198 0.315, 1.145 0.122 
Sarcomatoid component (< 50% vs ≥ 50%) 4.399 2.217 1.638, 11.81 0.003** 
Necrosis 2.102 0.755 1.040, 4.249 0.039* 
Pleural thickening 0.926 0.056 0.822, 1.043 0.205 
     
Interaction terms     
Age#Pleural thickness 1.001 0.0008 0.999, 1.003 0.071 
Chemotherapy#Pleural thickness 0.986 0.014 0.960, 1.013 0.317 
Radiotherapy#sarcomatoid 
component(dichotomous) 
0.131 0.080 0.040, 0.433 0.001 
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Figure Legends: 
 
Figure 1: Total patients with malignant pleural mesothelioma, 2005-2015, Guy's Hospital, London 
 
 
Figure 2: (a) Kaplan-Meier estimates of overall survival (OS); (b) Kaplan-Meier estimates of 
overall survival by surgery (PD) vs. chemotherapy/best supportive care 
 
Figure 3. Kaplan-Meier estimates of overall survival by sarcomatoid component as a dichotomous 
variable (<50% vs. ≥50%) 
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